Compare Expedia Group Inc (EXPE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Expedia Group (EXPE) trades at $271.44, up 4.86% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical signal, trading near resistance at $275, with solid fundamentals including a P/E of 16.99 and robust revenue growth to $14.73B in 2025. Recent news highlights competitive threats from AI agents but also underscores Expedia's strategic partnerships and B2B booking strength.

The outlook remains positive with a consensus price target of $335.06, implying 23% upside, supported by earnings momentum and market share gains. Key risks include AI disruption in travel booking and competitive pressures. Institutional sentiment is mixed but leans bullish, with growth in operating cash flow to $3.9B in 2025 providing a solid foundation.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.